Date | Title | Description | |
---|---|---|---|
10 May 2023 | On P&L | The Company releases the press release related to the first quarter 2023 financial results | Download |
10 May 2023 | On P&L | The Company releases the first quarter 2023 financial results presentation | Download |
25 Apr 2023 | On business and financial situation | ROVI commences clinical development of a new three-monthly formulation of Letrozole (Letrozole LEBE) | Download |
21 Feb 2023 | On business and financial situation | The Company releases the full year 2022 financial results presentation. | Download |
21 Feb 2023 | On business and financial situation | The Company releases the press release related to the full year 2022 financial results. | Download |
Pages
Date | Title | Description | |
---|---|---|---|
11 Jun 2024 | Share buy-back , stabilisation and treasury stock programmes | Share Buyback Program: transactions conducted between 7 June 2024 and 11 June 2024 and end of the share buyback program | Download |
07 Jun 2024 | Share buy-back , stabilisation and treasury stock programmes | Share Buyback Program: transactions conducted between 31 May and 6 June 2024 | Download |
31 May 2024 | Share buy-back , stabilisation and treasury stock programmes | Share Buyback Program: transactions conducted between 24 May and 30 May 2024 | Download |
24 May 2024 | Share buy-back , stabilisation and treasury stock programmes | Share Buyback Program: transactions conducted between 17 May and 23 May 2024 | Download |
21 May 2024 | Announcement of general shareholders’ meeting | Publication of the announcement of the call to the General Shareholders’ Meeting and the documentation related thereto. | Download |
Pages
Date | Title | Description | |
---|---|---|---|
26 Feb 2019 | Información sobre resultados | ROVI releases the presentation related to the full year 2018 results | Download |
26 Feb 2019 | Información sobre resultados | ROVI releases the press release related to the full year 2018 results | Download |
15 Feb 2019 | Others on business performance and financial information | ROVI acquires rights to Dexchlorpheniramine Maleate in the Spanish and French markets | Download |
09 Jan 2019 | Others on business performance and financial information | ROVI informs about the adquisition of Falithrom® for the German market | Download |
08 Jan 2019 | Liquidity contracts and specialists | Liquidity contract: transactions conducted in the fourth quarter of 2018 | Download |